Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Study to Assess Suppression of HIV-1 Replication Following Substitution of Stable Combination Antiretroviral Therapy With a PRO 140 (Monoclonal CCR5 Antibody) Monotherapy in Adult Subjects With HIV-1 Infection

NCT02175680 is registered in ClinicalTrials.gov with CytoDyn, Inc. as lead sponsor.

NCT NCT02175680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02175680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Study to Assess Suppression of HIV-1 Replication Following Substitution of Stable Combination Antiretroviral Therapy With a PRO 140 (Monoclonal CCR5 Antibody) Monotherapy in Adult Subjects With HIV-1 Infection
Lead sponsor
CytoDyn, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 16, 2014
Completion date
February 2, 2015
Enrollment
43 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, human immunodeficiency virus